** Pfizer can resume its pursuit of AstraZeneca fromtoday as 6-month cooling-off period ends but chances of a freshbid seen as slim, especially after the U.S. drugmaker's bigoncology deal with Merck KGaA last week.
** Jefferies analysts reckon Mylan, which is buyingsome of Abbott's established drugs, now the most likelytarget for Pfizer, with GlaxoSmithKline "a wild card",since buying top UK drugmaker would provoke political storm.
** Actavis, once seen as main "Plan B" target forPfizer, may now also be off the table following its proposedacquisition of Allergan.
** AstraZeneca shares are flat in early trade. (RM: ben.hirschler.thomsonreuters.com@reuters.net)
Astrazeneca (AZN)
Glaxosmithkline (GSK)
